1. EachPod
EachPod
CME in Minutes: Education in Oncology & Hematology - Podcast

CME in Minutes: Education in Oncology & Hematology

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

Medicine Science Health & Fitness Life Sciences
Update frequency
every 6 days
Average duration
16 minutes
Episodes
144
Years Active
2022 - 2025
Share to:
Patrick Forde, MB, BCh - Keeping the Dialogue Open in Early-Stage NSCLC: Instituting a Multidisciplinary Approach

Patrick Forde, MB, BCh - Keeping the Dialogue Open in Early-Stage NSCLC: Instituting a Multidisciplinary Approach

Please visit answersincme.com/GSN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and thoracic surgery di…
00:15:53  |   Mon 18 Dec 2023
Vishal A. Patel, MD - Making Headway in Treating Resectable Cutaneous Squamous Cell Carcinoma: Setting Sights on Neoadjuvant Immunotherapy

Vishal A. Patel, MD - Making Headway in Treating Resectable Cutaneous Squamous Cell Carcinoma: Setting Sights on Neoadjuvant Immunotherapy

Please visit answersincme.com/JEX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses t…
00:14:21  |   Mon 18 Dec 2023
Adam Brufsky, MD, PhD - Getting Real With Patients During Clinical Decision-Making: The Value of Sharing Real-World Evidence About CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer

Adam Brufsky, MD, PhD - Getting Real With Patients During Clinical Decision-Making: The Value of Sharing Real-World Evidence About CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer

Please visit answersincme.com/VVM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the relevan…
00:17:23  |   Mon 18 Dec 2023
Wolfgang Miesbach, MD, PhD - Gene Therapy in Hemophilia A: Redefining the Treatment Paradigm

Wolfgang Miesbach, MD, PhD - Gene Therapy in Hemophilia A: Redefining the Treatment Paradigm

Please visit answersincme.com/MWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in coagulation disorders discusse…
00:16:28  |   Tue 05 Dec 2023
Jorge Cortes, MD - Third-Line Therapies in Chronic Myeloid Leukemia: Evolving to Overcome the Limitations of Early-Generation Tyrosine Kinase Inhibitors

Jorge Cortes, MD - Third-Line Therapies in Chronic Myeloid Leukemia: Evolving to Overcome the Limitations of Early-Generation Tyrosine Kinase Inhibitors

Please visit answersincme.com/RPM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses available t…
00:13:38  |   Mon 13 Nov 2023
Asa Radix, MD, PhD, MPH - A Call to Action to Prevent Cervical Cancer in Transgender and Nonbinary Populations: Patient-Centered Strategies to Increase Screening Rates

Asa Radix, MD, PhD, MPH - A Call to Action to Prevent Cervical Cancer in Transgender and Nonbinary Populations: Patient-Centered Strategies to Increase Screening Rates

Please visit answersincme.com/UJD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in transgender medicine discusses…
00:13:22  |   Tue 31 Oct 2023
Trisha Wise-Draper, MD, PhD - Empowering Precision Decisions: PD-1 Inhibitor-Based Therapies and Biomarker Testing in R/M HNSCC

Trisha Wise-Draper, MD, PhD - Empowering Precision Decisions: PD-1 Inhibitor-Based Therapies and Biomarker Testing in R/M HNSCC

Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line …
00:14:19  |   Wed 11 Oct 2023
Richard Finn, MD - Improving Patient Outcomes in Advanced Biliary Tract Cancer: Evaluating the Promise of Immunotherapy Plus Chemotherapy Combinatorial Approaches

Richard Finn, MD - Improving Patient Outcomes in Advanced Biliary Tract Cancer: Evaluating the Promise of Immunotherapy Plus Chemotherapy Combinatorial Approaches

Please visit answersincme.com/EKH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses frontline i…
00:14:23  |   Mon 25 Sep 2023
Matthew R. Smith, MD, PhD - Combined Systemic Therapy to Combat Metastatic Hormone-Sensitive Prostate Cancer

Matthew R. Smith, MD, PhD - Combined Systemic Therapy to Combat Metastatic Hormone-Sensitive Prostate Cancer

Please visit answersincme.com/WGA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of…
00:09:17  |   Fri 22 Sep 2023
Sapna P. Patel, MD - Enhancing Neoadjuvant and Adjuvant Treatment in Resectable Melanoma: Is Timing the Key to Improved Outcomes?

Sapna P. Patel, MD - Enhancing Neoadjuvant and Adjuvant Treatment in Resectable Melanoma: Is Timing the Key to Improved Outcomes?

Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of …
00:14:54  |   Tue 19 Sep 2023
Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies

Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies

Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-ce…
00:16:50  |   Tue 19 Sep 2023
Eric K. Singhi, MD / Charu Aggarwal, MD, MPH - It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC

Eric K. Singhi, MD / Charu Aggarwal, MD, MPH - It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC

Please visit answersincme.com/ZRV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in lung carcinoma discuss the l…
00:16:27  |   Tue 05 Sep 2023
Alexander I. Spira, MD, PhD, FACP - Breaking News in NSCLC: The Latest Evidence on Emerging Antibody Drug Conjugates Targeting TROP2

Alexander I. Spira, MD, PhD, FACP - Breaking News in NSCLC: The Latest Evidence on Emerging Antibody Drug Conjugates Targeting TROP2

Please visit answersincme.com/DEV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses TROP2-di…
00:15:03  |   Tue 05 Sep 2023
Jamie E. Chaft, MD - Enhancing Outcomes for Patients With Resected, Early-Stage NSCLC: A Piercing Evaluation of the Clinical Support for Adjuvant Immunotherapies

Jamie E. Chaft, MD - Enhancing Outcomes for Patients With Resected, Early-Stage NSCLC: A Piercing Evaluation of the Clinical Support for Adjuvant Immunotherapies

Please visit answersincme.com/VET860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the use of adju…
00:14:51  |   Wed 23 Aug 2023
Stephen Lam Chan, MD - Recalibrating Survival: Available and Recently Approved Immunotherapy-Based Combination Approaches in Unresectable HCC

Stephen Lam Chan, MD - Recalibrating Survival: Available and Recently Approved Immunotherapy-Based Combination Approaches in Unresectable HCC

Please visit answersincme.com/TZQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in clinical oncology discusses op…
00:13:01  |   Thu 17 Aug 2023
Enriqueta Felip, MD, PhD / David Harpole, MD - Reflecting on the Role of Perioperative Immunotherapeutic Regimens for Resectable Non–Small-Cell Lung Cancer: Evaluating the Evidence to Determine Better Pathways of Care

Enriqueta Felip, MD, PhD / David Harpole, MD - Reflecting on the Role of Perioperative Immunotherapeutic Regimens for Resectable Non–Small-Cell Lung Cancer: Evaluating the Evidence to Determine Better Pathways of Care

Please visit answersincme.com/XQE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in non–small-cell lung cancer (…
00:16:50  |   Thu 27 Jul 2023
Eric Jonasch, MD - Optimizing Long-Term Care With Guideline-Recommended Systemic Treatment Options for von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

Eric Jonasch, MD - Optimizing Long-Term Care With Guideline-Recommended Systemic Treatment Options for von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

Please visit answersincme.com/XJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and urology discuss gui…
00:13:56  |   Thu 27 Jul 2023
Saad Z. Usmani, MD, MBA, FACP / Gareth J. Morgan, MD, PhD - Strength in Numbers: Triplet Combination Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) Special Patient Populations

Saad Z. Usmani, MD, MBA, FACP / Gareth J. Morgan, MD, PhD - Strength in Numbers: Triplet Combination Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) Special Patient Populations

Please visit answersincme.com/MMD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in multiple myeloma discuss tri…
00:13:48  |   Fri 07 Jul 2023
Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?

Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?

Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses t…
00:13:17  |   Mon 03 Jul 2023
Ticiana Leal, MD - Inspiring Improved Outcomes in Advanced NSCLC: A Patient-Centered Approach to Integrating Combination Locoregional and Immunotherapy Into Care

Ticiana Leal, MD - Inspiring Improved Outcomes in Advanced NSCLC: A Patient-Centered Approach to Integrating Combination Locoregional and Immunotherapy Into Care

Please visit answersincme.com/TSM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the rationa…
00:13:39  |   Mon 03 Jul 2023
Disclaimer: The podcast and artwork embedded on this page are the property of Answers in CME, 71 Broadway 2B, Suite #185 New York, NY 10006. This content is not affiliated with or endorsed by eachpod.com.